PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2005 December; 6(4): E618–E625.
Published online 2005 December 7. doi:  10.1208/pt060476
PMCID: PMC2750609

Adsorption of meloxicam on porous calcium silicate: Characterization and tablet formulation

Abstract

The purpose of the present study was characterization of microparticles obtained by adsorption of poorly water soluble drug, meloxicam, on a porous silicate carrier Florite RE (FLR) and development of a tablet formulation using these microparticles, with improved drug dissolution properties. The study also reveals the use of FLR as a pharmaceutical excipient. Meloxicam was adsorbed on the FLR in 2 proportions (1[ratio]1 and 1[ratio]3), by fast evaporation of solvent from drug solution containing dispersed FLR. Drug adsorbed FLR microparticles were evaluated for surface topography, thermal analysis, X-ray diffraction properties, infrared spectrum, residual solvent, micromeritic properties, drug content, solubility, and dissolution studies. Microparticles showed bulk density in the range of 0.10 to 0.12 g/cm3. Dissolution of drug from microparticles containing 1[ratio]3, drug[ratio]FLR ratio was faster than microparticles containing 1[ratio]1, drug[ratio]FLR ratio. These microparticles were used for formulating directly compressible tablets. Prepared tablets were compared with a commercial tablet. All the prepared tablets showed acceptable mechanical properties. Disintegration time of prepared tablets was in the range of 18 to 38 seconds, and drug dissolution was much faster in both acidic and basic medium from prepared tablets as compared with commercial tablet. The results suggest that FLR provides a large surface area for drug adsorption and also that a reduction in crystallinity of drug occurs. Increase in surface area and reduction in drug crystallinity result in improved drug dissolution from microparticles.

Keywords: Florite RE, meloxicam, adsorption, microparticles, dissolution

Full Text

The Full Text of this article is available as a PDF (292K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413–420. doi: 10.1023/A:1016212804288. [PubMed] [Cross Ref]
2. Meriani F, Coceani N, Sirotti C, Voinovich D, Grassi M. In vitro nimesulide absorption from different formulations. J Pharm Sci. 2004;93:540–552. doi: 10.1002/jps.10555. [PubMed] [Cross Ref]
3. Perrut M, Jung J, Leboeuf F. Enhancement of dissolution rate of poorly-soluble active ingredients by supercritical fluid processes Part I. Micronization of neat particles. Int J Pharm. 2005;288:3–10. doi: 10.1016/j.ijpharm.2004.09.007. [PubMed] [Cross Ref]
4. Kinoshita M, Baba K, Nagayasu A, et al. Improvement of solubility and oral bioavailability of a poorly water-soluble drug, TAS-301, by its melt-adsorption on a porous calcium silicate. J Pharm Sci. 2002;91:362–370. doi: 10.1002/jps.10026. [PubMed] [Cross Ref]
5. Ambike AA, Mahadik KR, Paradkar A. Stability study of amorphous valdecoxib. Int J Pharm. 2004;282:151–162. doi: 10.1016/j.ijpharm.2004.06.009. [PubMed] [Cross Ref]
6. Chowdary KPR, Hymavathi R. Enhancement of dissolution rate of meloxicam. Ind J Pharm Sci. 2001;63:150–154.
7. Smirnova I, Suttiruengwong S, Seiler M, Arlt W. Dissolution rate enhancement by adsorption of poorly soluble drugs on hydrophilic silica aerogels. Pharm Dev Technol. 2004;9:443–452. doi: 10.1081/PDT-200035804. [PubMed] [Cross Ref]
8. Streubel A, Siepmann J, Bodmeier R. Floating matrix tablet based on low density foam powder: effects of formulation and processing parameters on drug release. Eur J Pharm Sci. 2003;18:37–45. doi: 10.1016/S0928-0987(02)00223-3. [PubMed] [Cross Ref]
9. Yuasa H, Takashima Y, Kanaya Y. Studies on the development of intragastric floating and sustained release preparation. I. Application of calcium silicate as a floating carrier. Chem Pharm Bull (Tokyo) 1996;44:1361–1366.
10. Streubel A, Siepmann J, Bodmeier R. Floating microparticles based on low density foam powder. Int J Pharm. 2002;241:279–292. doi: 10.1016/S0378-5173(02)00241-7. [PubMed] [Cross Ref]
11. Ito Y, Arai H, Uchino K, Iwasaki K, Shibata N, Takada K. Effect of adsorbents on the absorption of lansoprazole with surfactant. Int J Pharm. 2005;289:69–77. doi: 10.1016/j.ijpharm.2004.10.010. [PubMed] [Cross Ref]
12. Salis A, Sanjust E, Solinas V, Monduzzi M. Characterization of Accurel MP 1004 polypropylene powder and its use as a support for lipase immobilization. J Mol Cat B Enz. 2003;24–25:75–82. doi: 10.1016/S1381-1177(03)00112-7. [Cross Ref]
13. Byrne RS, Deasy PB. Use of commercial porous ceramic particles for sustained drug delivery. Int J Pharm. 2002;246:61–73. doi: 10.1016/S0378-5173(02)00357-5. [PubMed] [Cross Ref]
14. Yuasa H, Asahi D, Takashima Y, Kanaya Y, Shinozawa K. Application of calcium silicate for medicinal preparation. I. Solid preparation adsorbing an oily medicine to calcium silicate. Chem Pharm Bull (Tokyo) 1994;42:2327–2331. [PubMed]
15. Yuasa H, Akutagawa M, Hashizume T, Kanaya Y. Studies on internal structure of tablets. VI. Stress dispersion in tablets by excipients. Chem Pharm Bull (Tokyo) 1996;44:378–382. [PubMed]
16. Kinoshita M, Baba K, Nagayasu A, et al. Highly stabilized amorphous 3-bis(4-methoxyphenyl)methylene-2-indolinone (TAS-301) in melt-adsorbed products with silicate compounds. Drug Dev Ind Pharm. 2003;29:523–529. doi: 10.1081/DDC-120018641. [PubMed] [Cross Ref]
17. Jackson RL, Jason MD. Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbird LE, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 2000. pp. 713–714.
18. Naidu NB, Chowdary KP, Murthy KV, Satyanarayana V, Hayman AR, Becket G. Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems. J Pharm Biomed Anal. 2004;35:75–86. doi: 10.1016/j.jpba.2004.01.003. [PubMed] [Cross Ref]
19. Ghorab MM, Abdel-Salem HM, El-Sayad MA, Mekhel MM. Tablet formulation containing meloxicam and β-cyclodextrin: mechanical characterization and bioavailability evaluation. AAPS PharmSciTech. 2004;5:E59–E59. doi: 10.1208/pt050459. [PMC free article] [PubMed] [Cross Ref]
20. Seedher N, Bhatia S. Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech. 2003;4:E33–E33. doi: 10.1208/pt040333. [PMC free article] [PubMed] [Cross Ref]
21. Cantera RG, Leza MG, Bachiller CM. Solid phases of tenoxicam. J Pharm Sci. 2002;91:2240–2251. doi: 10.1002/jps.10207. [PubMed] [Cross Ref]
22. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.ICH Harmonised Tripartite Guideline. Impurities: guideline for residual solvents Q3C. Geneva, Switzerland: ICH; 1997.
23. Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123–133. doi: 10.1016/S0928-0987(01)00095-1. [PubMed] [Cross Ref]
24. Charumanee S, Okonoki S, Sirithunyalug J. Improvement of the dissolution rate of piroxicam by surface solid dispersion. CMU J. 2004;3:77–84.

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists